Capital International Inc. CA Increases Position in Boston Scientific Co. (NYSE:BSX)

Capital International Inc. CA boosted its holdings in Boston Scientific Co. (NYSE:BSX) by 193.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 148,059 shares of the medical equipment provider’s stock after purchasing an additional 97,550 shares during the period. Capital International Inc. CA’s holdings in Boston Scientific were worth $13,225,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of BSX. Capital World Investors boosted its holdings in shares of Boston Scientific by 28.7% in the 4th quarter. Capital World Investors now owns 27,899,903 shares of the medical equipment provider’s stock worth $2,492,041,000 after buying an additional 6,216,199 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Boston Scientific by 0.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 4,914,442 shares of the medical equipment provider’s stock worth $438,979,000 after acquiring an additional 22,621 shares during the period. First Trust Advisors LP grew its position in shares of Boston Scientific by 160.9% during the 4th quarter. First Trust Advisors LP now owns 511,920 shares of the medical equipment provider’s stock valued at $45,725,000 after acquiring an additional 315,708 shares during the period. Forum Financial Management LP increased its stake in shares of Boston Scientific by 13.8% during the 4th quarter. Forum Financial Management LP now owns 13,336 shares of the medical equipment provider’s stock worth $1,191,000 after purchasing an additional 1,621 shares during the last quarter. Finally, GeoWealth Management LLC lifted its stake in Boston Scientific by 11.1% in the fourth quarter. GeoWealth Management LLC now owns 11,450 shares of the medical equipment provider’s stock valued at $1,023,000 after purchasing an additional 1,147 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Insiders Place Their Bets

In other news, Director Edward J. Ludwig sold 12,000 shares of the firm’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $105.48, for a total value of $1,265,760.00. Following the completion of the sale, the director now directly owns 24,398 shares of the company’s stock, valued at approximately $2,573,501.04. This trade represents a 32.97 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Daniel J. Brennan sold 67,333 shares of the business’s stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $105.24, for a total transaction of $7,086,124.92. Following the transaction, the chief financial officer now owns 225,808 shares in the company, valued at $23,764,033.92. This represents a 22.97 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 133,183 shares of company stock worth $13,948,476. 0.50% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on BSX shares. Argus set a $130.00 price target on Boston Scientific in a research report on Tuesday, February 18th. Royal Bank of Canada upped their price target on shares of Boston Scientific from $105.00 to $116.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. Deutsche Bank Aktiengesellschaft upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price objective for the company in a research note on Friday, January 10th. StockNews.com lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, March 8th. Finally, Morgan Stanley lifted their target price on Boston Scientific from $100.00 to $120.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. One research analyst has rated the stock with a hold rating, twenty-two have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $110.22.

Boston Scientific Trading Down 0.2 %

Shares of BSX stock opened at $95.08 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. Boston Scientific Co. has a 1-year low of $66.80 and a 1-year high of $107.17. The business has a 50-day moving average of $99.46 and a 200 day moving average of $94.41. The stock has a market capitalization of $140.63 billion, a PE ratio of 76.06, a P/E/G ratio of 2.79 and a beta of 0.73.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. As a group, sell-side analysts anticipate that Boston Scientific Co. will post 2.85 earnings per share for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.